Strides Shasun has received approval from the US health regulator for Abacavir tablets used in the treatment of HIV.
In a BSE filing, Strides Shasun said today: “It has received approval from the United States Food and Drug Administration (USFDA) for Abacavir tablets USP, 300 mg.’’
The product will be manufactured at the company’s USFDA approved facility at Bengaluru and marketed by Strides in the US market.
“The product will be launched immediately,” it added.
According to IMS sales data, the US market for Abacavir is approximately $30 million.
Strides Shasun stock was trading higher by 1.63 per cent at Rs 1,060 on the BSE.